Predictive disease control

Because of their after-infection and antisporulation activity against scab, the EBI fungicides are especially suitable for use in predictive disease control programs. Predictive disease control is an important part of integrated pest management programs on apples. A predictive system means control measures are applied after the onset of infection. Small special purpose computers with field... 

Khambata-Ford S et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. Journal of Clinical Oncology 2007 25 3230-3237. 

Scitovsky et al. (1986) calculated the average cost per AIDS-related hospital admission as US 9,024 ranging from US 7,026 to US 23,425. A more comprehensive picture is presented by Scitovsky and Rice (1987), who estimated provider cost of the AIDS epidemic in the United States in 1985, 1986, and 1991, based on prevalence estimates provided by the Center for Disease Control (CDC). They predicted that the core provider costs of AIDS would rise from US 630 million in 1985 to US 1.1 billion in 1986 and to US 8.5 billion in 1991. The authors compared their estimates of the cost of AIDS in the USA with the estimates for end-stage renal disease (US 2.2 billion), traffic accidents (US 5.6 billion), lung cancer (US 2.7 billion), and breast cancer (US 2.2 billion). They concluded that the core provider costs of AIDS were relatively low in comparison with the provider costs of all illness as well as the costs of these other diseases. However, they also assessed the non-care costs (e.g., for research) to rise from US 319 million in 1985 to US 542 million in 1986 and to US 2.3 billion in 1991. 

Until October 2001, no deaths from bioterrorism were reported in the U.S. On September 11, 2001, after the attacks on New York City and Washington, the Centers for Disease Control recommended that the nation increase its surveillance for unusual disease occurrences or clusters, asserting that they could be sentinel indicators of bioterrorist attacks. As predicted, cases of anthrax were reported in Florida, New York City, the District of Columbia, and New Jersey. Over the years, it has become evident that not only is biological warfare attractive to governments, it is equally attractive to terrorist cells because the agents are relatively inexpensive and easy to make. 

Current predictions suggest that the twin epidemics of obesity and diabetes worldwide will result in an increase in CVD rates, which have sharply declined over the past 30 years, after the introduction of effective lipid-lowering and antihypertensive therapies. The World Health Organization (WHO) reported that in 2002, deaths from CVD outnumbered deaths from the major communicable diseases (AIDS, tuberculosis, and malaria) by 3 to 1 (2). By 2015, an estimated 20 million people will die annually from CVD. Therefore, with the advent of the new millennium, there is a sense of urgency to address the burden of chronic cardiometabolic diseases worldwide. The information on the prevalence and etiology of cardiometabolic diseases, which is cited in this section was obtained from the WHO and Centers for Disease Control (CDC) websites (2-6). 

The nature of a particular disease can help you predict whether control is necessary hence the importance of disease identification. Noninfectious diseases do not spread from one plant to the next. For instance, leaf yellowing due to iron deficiency on an azalea planted in alkaline soil will not spread to nearby healthy azaleas planted in acidic soil. While you should take steps to revitalize the affected plants, you won t have to do anything to protect the healthy plants. 

Centers for Disease Control and Prevention (CDC), which estimated a prevalence in 2001 of 7.9% in adults. This is equivalent to 16.7 million people. Because at least 30% of all prevalent cases are undiagnosed, the total number may have been almost 22 million. Note that in 1987, the prevalence of diagnosed diabetes was 6.8 million. This large increase in diabetes has been observed globally. The prevalence of diabetes in adults worldwide was estimated to be 4.0% in 1995 and anticipated to rise to 5.4% by the year 2025. The prediction is that in 2025 there will be 300 million adults with diabetes, greater than 75% of whom will live in developing countries. These statistics have led to diabetes being described as one of the main threats to human health in the twenty-first century. The prevalence of diabetes mellitus increases with age, and approximately half of all cases occur in people older than 55 years. In the United States, -20% of the population older than 65 years have diabetes. There is racial predilection, and by the age of 65, 33%, 25%, and 17% of Hispanics, blacks, and whites, respectively, in the United States have diabetes mellitus. In 2002 diabetes mellitus was estimated to be responsible for 132 billion in healthcare expenditures in the United States. The direct costs were 92 billion, with 50% of that incurred by those older than 65 years. An estimated 186,000 deaths annually are attributable to diabetes. In fact, American women are twice as likely to die from diabetes mellitus as from breast cancer. Approximately one in five American healthcare dollars spent in 2002 was for people with diabetes mellitus. 

DHA (docosahexaenoic Acid) lower serum DHA levels predicted significantly increased risk of developing Alzheimer s Disease. controlled clinical trials showed cognitive improvement in patients with vascular dementia or Alzheimer s Disease. 

Furthermore, we predict that the dendritic state [312] will undoubtedly provide the quintessential scientific bridge by which both abiotic molecular level scientists will be able to communicate and collaborate on such critical issues as disease control, increased agricultural production and finally longevity with enhanced quality of life. It is with these thoughts and premises that we should be very excited about the future of dendritic macromolecular technology and the role its supra-properties will provide as we enter the next millennium. 

All such animal procedures suffer from the obvious and basic problem that laboratory animals do not behave like humans and that humans cannot reliably interpret their reactions and behaviour. Thus we know that Parkinson s disease is caused by a degeneration of the dopaminergic nigrostriatal tract but its lesion in animals does not produce any condition which resembles human Parkinsonism, except in primates, even though there are functional tests (e.g. rotational movements) which readily establish that loss of dopamine function and also respond to its augmentation (Chapter 15). By contrast, there are many ways, e.g. electrical stimulation and the administration of certain chemicals, to induce convulsions in animals and a number of effective antiepileptic drugs have been introduced as a result of their ability to control such activity. Indeed there are some tests, as well as animals with varied spontaneous seizures, that are even predictive of particular forms of epilepsy. But then convulsions are a very basic form of activity common to most species and epileptic seizures that are characterised by behavioural rather than motor symptoms are more difficult to reproduce in animals. 

Muscarinic and dopaminergic pathways in the CNS interact in control of numerous pathways implicated in diseases, especially those controlling involuntary motor systems. Muscarinic effects on dopamine release are mediated in several ways via different mAChR subtypes. Thus mAChR facilitation of DA release appears to involve M4 receptors on GABA projection neurons to the striatum, while M3 receptors on striatal DA neurons are predicted to inhibit striatal DA release [12],... 

---